Previous close | 104.50 |
Open | 108.84 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 108.84 - 108.84 |
52-week range | 91.55 - 114.80 |
Volume | |
Avg. volume | 11,672 |
Market cap | 138.947B |
Beta (5Y monthly) | 0.36 |
PE ratio (TTM) | 19.40 |
EPS (TTM) | 5.61 |
Earnings date | N/A |
Forward dividend & yield | 3.52 (3.37%) |
Ex-dividend date | 06 May 2022 |
1y target est | N/A |
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,527,121,390 €Registered office : 54, rue La Boétie - 75008 Paris - FranceRegistered at the Paris Commercial and Companies Registry under n
Mega-blockbuster Dupixent was just given the FDA's green light to treat patients with a chronic, progressive inflammatory disease.
Global biopharmaceutical company Sanofi (NASDAQ: SNY) encountered setbacks while developing its COVID-19 vaccine, and only this year reported results from late-stage clinical trials. Sanofi opted for the more traditional protein-based technology for its COVID-19 vaccine, Vidprevtyn, rather than the mRNA technology of Pfizer-BioNTech's Comirnaty and Moderna's Spikevax. The mRNA technology delivers genetic code instructing the body's cells to make the protein, while the more traditional approach produces the protein in a lab before injecting it into the body.